Determination of Regulatory Review Period for Purposes of Patent Extension; BELSOMRA

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for BELSOMRA, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO) for patent extension. The FDA is publishing this notice as required by law.